Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial

Chemotherapy Clinical Trial

Official title:

Anti-PD-1 Antibody Camrelizumab Combined With Albumin-bound Paclitaxel for Recurrent and Persistent Advanced Cervical Cancer Refractory to Platinum-based Chemotherapy: A Single Arm, Multi-Center, Open, Phase II Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05290935
• Other study ID #: REPACC-3
• Status: Recruiting
• Phase: Phase 2
• Start date: March 13, 2022
• Est. completion date: March 13, 2024

Study information

• Verified date: March 2022
• Source: Peking Union Medical College Hospital
• Contact: Lei Li, M.D.
• Phone: 10-139-1198-8831
• Email: lileigh[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a updated trial of NCT04188860 as a multi-center study. For recurrent or persistent advanced cervical cancer patients, the first-line chemotherapy was based on platinum. However, if they were refractory to platinum-based chemotherapy, there were no other more effective medications or treatment. The marketing of anti-PD-1 antibody has provided an opportunity of curative management. This single arm, open, phase II trial would recruit 122 eligible patients. A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel would be given for all patients. The primary end is overall response rate (ORR). The second ends include progression-free survival, overall survival, disease control rate, remission duration, and adverse events. A molecular testing, mainly consisting of genomic analysis, will be carried in the oncologic tissues.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 122
• Est. completion date: March 13, 2024
• Est. primary completion date: December 13, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Female of 18-75 years old
• Eastern Cooperative Oncology Group score 0-1
• Pathological confirmed of uterine cervical adenocarcinoma, squamous carcinoma, or adenosquamous carcinoma, with stage IA1 (with lymph-vascular space invasion) to IVB, which had accepted radical treatment for the purpose of cure
• Having accepted at least one regimen of platinum-based chemotherapy after the diagnosis of recurrent or persistent advanced cervical cancer, and having an interval of at least 4 weeks since fulfilling the last treatment regimen
• At least one measurable lesion defined by Response Evaluation Criteria in Solid Tumors (RECIST) guideline 1.1
• Anticipative survival period of 3 months or more
• Lab testing within reference ranges
• With appropriate contraception
• Provided consents of participating the trial

Exclusion Criteria:

• With brain metastasis
• With addiction to psychiatric medications or with mental disorders
• With following history and/or complications: autoimmune disease; systematic utilization of corticosteroids (with equivalent of prednison of > 10 mg/day) or other immunosuppressors within 14 days; utilization of antitumor vaccine or other immunostimulation treatment with 3 months; exposure to PD-1 antibody, or PD-L1 antibody, or PD-L2 antibody, or cytotoxic T lymphocyte-associated antigen-4 antibody; history of other malignancies; pulmonary tuberculosis; interstitial pneumonia or related history; active hepatitis; positive testing of human immunodeficiency
• With adverse effects more than Common Terminology Criteria for Adverse Events grade 1 (except for alopecia), which caused by previous anti-tumor treatment
• With infective disease which need systematic treatment within 14 days
• With severe open trauma, fracture or major surgery with past 4 weeks
• With potential allergy or intolerance to study regimens
• Not eligible for the study judged by researchers

Related Conditions & MeSH terms

• Anti-PD-1 Antibody
• Carcinoma
• Chemotherapy
• Immune Checkpoint Inhibitors
• Persistent Advanced Cervical Carcinoma
• Recurrent Cervical Carcinoma
• Uterine Cervical Neoplasms

Intervention

Drug:
• Anti-PD-1 antibody camrelizumab
Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months
• Albumin-bound paclitaxel
Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses

Locations

Country	Name	City	State
China	Lei Li	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Lei Li

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate	The rates of complete and partial remission	One year
Secondary	Progression-free survival	The length of time during and after the treatment of the cancer, that a patient lives with the disease but it does not get worse	One year
Secondary	Overall survival	The length of time from either the date of diagnosis or the start of treatment for the cancer, that patients diagnosed with the disease are still alive	One year
Secondary	Disease control rate	The rates of complete and partial remission, and stable disease	One year
Secondary	Adverse event rates	The rates of adverse events judged by Common Terminology Criteria for Adverse Events	One year